ASCO 2022 | AMBER: cobolimab monotherapy & in combination with PD-1 inhibitors nivolumab or dostarlimab

Gerald Steven Falchook, MD, Sarah Cannon Research Institute at HealthONE, Denver, CO, discusses results of the multi-center, open-label Phase I AMBER (NCT02817633) trial investigating the TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab. Primary endpoints were safety, tolerability, and recommended Phase II dose. 104 patients were included in the trial. The most common cancers were non-small cell lung cancer (NSCLC), skin, and peritoneal mesothelioma. Results demonstrated cobolimab plus dostarlimab were well tolerated and exhibited preliminary antitumor activity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.